Satranidazole 

Satranidazole is an orally active insecticide and antimicrobial agent with high electron affinity. Satranidazole forms reduced nitro intermediates, which interact with DNA, causing helix instability, strand breakage and release of thymidine derivatives. Satranidazole exhibits antitrichomonal activity against Trichomonas vaginalis and Trichomonas foetus, and antiamoebic activity in rodent models of hepatic amoebiasis and caecal amoebiasis. Satranidazole inhibits the replication of bacteriophage φX174 DNA. Satranidazole can be used in research related to caecal amoebiasis, trichomoniasis and anaerobic bacterial infections^[1][2].

Satranidazole induces extensive DNA damage in *E. coli* at compound-to-nucleotide ratios of 0.5:1 and 1:1, including helix destabilization, strand breakage, thymidine release, and reduced viscosity^[1].
Satranidazole inactivates bacteriophage φX174 DNA at a compound-to-nucleotide ratio of 1:1, with a T₃₇ of 2.41 h and an R₃₇ of 3.85, indicating the presence of biologically relevant DNA damage^[1].
Satranidazole (8 h) potently inhibits reference strains and clinical isolates of anaerobic bacteria in vitro, with an MIC₉₀ of 0.25 mg/L against 50 clinical isolates, and its MIC values are lower than those of the control drugs in most tested strains^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Satranidazole exhibits superior activity to Metronidazole (HY-B0318) in a mouse model of caecal amebiasis^[1].
Satranidazole demonstrates amoebicidal activity in a golden hamster model of liver, caecal, or combined Entamoeba histolytica infection^[1].
Satranidazole exhibits superior activity to Metronidazole in a mouse model of subcutaneous Trichomonas vaginalis or Trichomonas foetus infection^[1].
Satranidazole (2-32 mg/kg; p.o.; 3 doses) exhibits potent protective activity against fatal Fusobacterium necrophorum septicaemia in mice, with an ED₅₀ of 2.10 mg/kg^[2].
Satranidazole (10-100 mg/kg; p.o.; twice) demonstrates dose-dependent bactericidal activity against subcutaneous Bacteroides fragilis abscesses in mice, achieving a 3-log cfu reduction at 10 mg/kg and complete sterilization at 100 mg/kg^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

289.27

C₈H₁₁N₅O₅S

56302-13-7

O=C1N(CCN1S(=O)(C)=O)C2=NC=C(N2C)[N+]([O-])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zahoor A, et al. Satranidazole: mechanism of action on DNA and structure-activity correlations. J Antimicrob Chemother. 1986;18(1):17-25.  [Content Brief]

  [2]. Gowrishankar R, et al. Satranidazole: experimental evaluation of activity against anaerobic bacteria in vitro and in animal models of anaerobic infection. J Antimicrob Chemother. 1985;15(4):463-470.  [Content Brief]